Ulixertinib

DB13930InvestigationalSmall molecule

Ulixertinib is a a novel, reversible, ATP-competitive ERK1/2 inhibitor with high potency and ERK1/2 selectivity . It is currently in clinical trials for the treatment of a wide range of...

Mechanism: Pharmacologically active on Mitogen-activated protein kinase 3 and Mitogen-activated protein kinase 1
Curator reviewed
Formula / weight: C₂₁H₂₂Cl₂N₄O₂ · 433.33 g/mol (avg)
Code names: BVD-523 · BVD-523FB · BVD-ERK · VRT752271

Resolves to

Compound

UNII16ZDH50O1UCAS869886-67-9ChEMBLCHEMBL3590106

Structure

InChIKeyKSERXGMCDHOLSS-LJQANCHMSA-NSMILES[H]N([C@H](CO)C1=CC(Cl)=CC=C1)C(=O)C1=CC(=CN1[H])C1=CC(=NC=C1Cl)N([H])C(C)C

Targets

P27361MAPK3P28482MAPK1P29323EPHB2

What you can answer from here — as of August 30, 2026

3Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

18Clinical trialsPhase, status and sponsor resolved per trial

6+ReferencesStructured and connected to the statements they support

Which drugs share a target with Ulixertinib, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account